Clinical outcomes of EGFR+ NSCLC pts treated with immune checkpoint inhibitors (ICI).

9069Background: ICIs have limited efficacy in EGFR+ NSCLC with ORR ~10% if PDL1 > 25% in ATLANTIC, yet ICIs are often used in later lines of therapy as pts and providers feel there may be little ri...